New drug cocktail shows promise for tough blood cancer

NCT ID NCT03478514

Ongoing Disease control Sponsor: Alliance Foundation Trials, LLC. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This phase II study tests a combination of two drugs, palbociclib and ibrutinib, in 39 patients with mantle cell lymphoma that has been treated before. The goal is to see if the combo can delay cancer progression. Patients take both pills daily in 28-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: palbociclib and ibrutinib
What this could lead to: If successful, this combination could offer a new treatment option for patients with mantle cell lymphoma who have already tried other therapies.
What could go wrong: This is a small, early-phase study with only 39 participants, so results may not apply to all patients. Side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B CELL LYMPHOMA MANTLE CELL LYMPHOMA

Contacts and locations

Locations

City of Hope National Medical Center

Duarte, California, 91010, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Medical University of South Carolina - Hollings Cancer Center

Charleston, South Carolina, 29425, United States
Ohio State University

Columbus, Ohio, 43210, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States
St. Joseph Mercy Hospital Cancer Care Center

Ypsilanti, Michigan, 48197, United States
University of Maryland, Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, 21201, United States
University of North Carolina

Chapel Hill, North Carolina, 27599, United States
Weill Cornell Medical College

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.